This pilot study investigated the use of autologous antigen-pulsed dendritic cells (DCs) as a vaccine for B-cell lymphoma. Four patients with follicular B-cell lymphoma received three or four infusions of antigen-pulsed DCs followed by subcutaneous injections of soluble antigen. All patients developed measurable antitumor immune responses, with one experiencing complete tumor regression, another partial regression, and a third resolving all disease evidence. Conventional treatments for low-grade non-Hodgkins lymphoma often induce tumor regression but are not curative. The study explored using the immune system to target tumor-specific antigens, particularly in B-cell malignancies where tumor-specific immunoglobulin receptors are present. Idiotype determinants, formed by the variable regions of immunoglobulin heavy and light chains, are antigens that can be recognized by the immune system. Anti-idiotype antibodies have shown effectiveness in targeting lymphoma cells. Animal studies have demonstrated that idiotype vaccines can induce host immunity against tumor challenge and cure established disease. A clinical trial using idiotype vaccination in B-cell lymphoma successfully induced anti-idiotype immune responses and tumor regression in humans. The study used autologous DCs pulsed with tumor-specific idiotype protein. DCs were isolated from peripheral blood and pulsed with antigen. The cells were then reinfused and followed by subcutaneous injections of soluble antigen. All patients developed strong humoral and cellular immune responses against the control protein KLH. Antitumor immune responses were also observed against the tumor idiotype protein. The vaccine was well tolerated, with mild side effects. The study demonstrated that antigen-pulsed DCs can stimulate clinically relevant immune responses in humans. The results suggest that DC-based vaccines may be a promising treatment for B-cell malignancies, as they can induce strong immune responses and lead to tumor regression in some patients. The study also highlights the potential of using DCs as a vaccine for other diseases, as they can present antigens effectively and stimulate immune responses. The use of DCs as a vaccine is an area of active research, with potential for enhancing antitumor immunity through cytokine application. The study indicates that DCs can be safely harvested, pulsed with antigen, and infused into humans without significant toxicity. The results suggest that antigen-pulsed DCs represent a powerful new vaccine capable of inducing cellular immune responses.This pilot study investigated the use of autologous antigen-pulsed dendritic cells (DCs) as a vaccine for B-cell lymphoma. Four patients with follicular B-cell lymphoma received three or four infusions of antigen-pulsed DCs followed by subcutaneous injections of soluble antigen. All patients developed measurable antitumor immune responses, with one experiencing complete tumor regression, another partial regression, and a third resolving all disease evidence. Conventional treatments for low-grade non-Hodgkins lymphoma often induce tumor regression but are not curative. The study explored using the immune system to target tumor-specific antigens, particularly in B-cell malignancies where tumor-specific immunoglobulin receptors are present. Idiotype determinants, formed by the variable regions of immunoglobulin heavy and light chains, are antigens that can be recognized by the immune system. Anti-idiotype antibodies have shown effectiveness in targeting lymphoma cells. Animal studies have demonstrated that idiotype vaccines can induce host immunity against tumor challenge and cure established disease. A clinical trial using idiotype vaccination in B-cell lymphoma successfully induced anti-idiotype immune responses and tumor regression in humans. The study used autologous DCs pulsed with tumor-specific idiotype protein. DCs were isolated from peripheral blood and pulsed with antigen. The cells were then reinfused and followed by subcutaneous injections of soluble antigen. All patients developed strong humoral and cellular immune responses against the control protein KLH. Antitumor immune responses were also observed against the tumor idiotype protein. The vaccine was well tolerated, with mild side effects. The study demonstrated that antigen-pulsed DCs can stimulate clinically relevant immune responses in humans. The results suggest that DC-based vaccines may be a promising treatment for B-cell malignancies, as they can induce strong immune responses and lead to tumor regression in some patients. The study also highlights the potential of using DCs as a vaccine for other diseases, as they can present antigens effectively and stimulate immune responses. The use of DCs as a vaccine is an area of active research, with potential for enhancing antitumor immunity through cytokine application. The study indicates that DCs can be safely harvested, pulsed with antigen, and infused into humans without significant toxicity. The results suggest that antigen-pulsed DCs represent a powerful new vaccine capable of inducing cellular immune responses.